NPCE Stock — NeuroPace Inc

Up next

Next earnings call

Nov 7, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 11, 2026

Q2 2026 earnings call transcript

call held Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$102.86M

Trailing 12 months

Net income (TTM)

−$19.11M

Trailing 12 months

Revenue growth YoY

+17.1%

Year over year

Operating margin

-13.3%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-2.4%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+3.8%

Year over year · more shares

Price change (1Y)

+33.5%

Trailing year

Short interest

2.8%

Latest settlement · 8.7 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 11, 2026

Q2 FY26

TL;DR. NeuroPace reported Q2 2026 RNS revenue of $22.5 million (21.3% growth) and raised full-year 2026 revenue guidance to $99.5M-$101.5M and adjusted gross margin to 82-83%, while the IGE PMA supplement received a not-approvable letter from the FDA prompting an SIR process.

Bullish

+ Q2 RNS system revenue grew 21.3% to $22.5 million, with first-half RNS growth of 20.4% in line with the long-term framework
+ Raised full-year 2026 total revenue guidance to $99.5M-$101.5M from $99M-$101M
+ Q2 adjusted EBITDA loss narrowed to $2.8M from $4.9M and GAAP net loss improved to $6.2M from $10.0M

Bearish

− FDA informed NeuroPace the IGE PMA supplement was not approvable in its current form, requesting additional information
− Management acknowledged IGE approval timing has slipped versus prior expectation of mid-2026
− Non-GAAP gross margin declined slightly to 83.4% from 84.0% on higher material costs
− Service revenue declined to $302K from $937K, a headwind of more than 300 basis points to total revenue growth

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −10%

below

Price vs 50-day avg −4%

below

RSI (14) 42

neutral

MACD trend Negative

52-week position 44%

mid-range

Momentum

relative strength

Very Weak

1-month return −7%

trailing

6-month return −6%

trailing

YTD return −11%

this year

Relative strength −18%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $14 › 200d $15 — 200d above 50d

Institutional flow Distributing

-1% holders QoQ · +18 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

2.79% of float · ▲ +4.9% MoM · 8.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

112 holders — near 3-yr high, broad support

Squeeze score 50

elevated · 0–100

Fundamentals

Strong

Revenue growth +25%

Y/Y

Gross margin 77%

expanding

EPS growth +29%

Y/Y

Free cash flow $-11.3M

Quant / Vol

risk profile

Very High

Volatility 62%

annualized · 1-yr

Max drawdown −33%

past year

ATR 4.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 3 of last 4

Latest guidance · from the 8-K filed Aug 11, 2026

2026

Non-GAAP gross margin 82% – 83%

GAAP gross margin 81.5% – 82.5%

full year 2026

Non-GAAP operating expenses Initiated $90M – $92M

Guided vs delivered · last 4 settled

Total revenue Full Year 2023

guided $62.5M – $63.5M

guided $62.5M – $63.5M $65.42M Beat +3.8%

Annual revenue 2022

guided $45M – $48M

guided $45M – $48M $45.52M In line

Total revenue first quarter 2022

guided $10M – $11M

guided $10M – $11M $11.37M Beat +8.3%

Full-year total revenue full-year 2021

guided $47M

guided $47M $45.18M Miss −3.9%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

2 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−10% Bearish

Price vs 50-day avg

−4% Neutral

RSI (14)

42 Neutral

MACD trend

Negative Bearish

52-week position

44% Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $14 › 200d $15 — 200d above 50d

Institutional flow Distributing

-1% holders QoQ · +18 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

2.79% of float · ▲ +4.9% MoM · 8.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

112 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $9 Now $14 · 44% Range high $19

vs 200-day avg -10% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted EBITDA from continuing operations (Non-GAAP) non-GAAP	-6.04M	Six Months Ended June 30, 2026	—
Non-GAAP cost of goods sold non-GAAP	7.65M	Six Months Ended June 30, 2026	—
Non-GAAP general and administrative expense non-GAAP	8.14M	Six Months Ended June 30, 2026	—
Non-GAAP gross margin non-GAAP	83.4%	Q2 2026	—
Non-GAAP loss from continuing operations non-GAAP	-6.17M	Six Months Ended June 30, 2026	—
Non-GAAP loss from operations non-GAAP	-$2.8M	Q2 2026	—
Non-GAAP net loss non-GAAP	-$3.9M	Q2 2026	—
Non-GAAP net loss from continuing operations non-GAAP	-8.35M	Six Months Ended June 30, 2026	—
Non-GAAP operating expenses non-GAAP	43.35M	Six Months Ended June 30, 2026	—
Non-GAAP research and development expense non-GAAP	12.75M	Six Months Ended June 30, 2026	—
Non-GAAP sales and marketing expense non-GAAP	22.46M	Six Months Ended June 30, 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
NPCE NeuroPace Inc this stock	$482.60M	-10.9%	+25.1%	—	2.8%
ABT Abbott Laboratories	$174.90B	-21.1%	+5.7%	28.1	1.1%
MDT Medtronic plc	$113.38B	-10.2%	+8.4%	21.8	1.3%
SYK Stryker Corp	$104.47B	-21.6%	+11.2%	28.2	2.0%
BSX Boston Scientific Corp	$63.59B	-54.2%	+12.5%	17.8	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

112

% held: 77.4%
Net QoQ: +108.1K sh
Top holder: Polar Capital Holdings Plc

Held Float

View

Held by Funds

Fund positions

114

View

Short & Settlement

Short Interest Rising

Shares short

956.2K

Days to cover: 8.7d
Change: +44.8K sh

View

Short Volume

Short vol %

16%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

2

Value: $29
As of: Sep 2, 2026

View

Off-Exchange

Off-exchange %

30.9%

Week of: Aug 24, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$100.0M

Net income (FY): $-21.5M
EPS diluted: $-0.66

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 8, 2026
This year: 12

View

Proposed Sales

Value

$404.8K

Shares: 25.0K
Filed: Dec 15, 2025

View

Exempt Offerings

Offering

$96.4M

Filed: Aug 31, 2020

View

Earnings & Events

Earnings Calls

Last call

Sep 8, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
NPCE	-3.2%	-6.7%	-6.1%	-6.1%	-10.9%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	-2.5%	-6.8%	-18.3%	-5.5%	-22.7%

NPCE · NeuroPace Inc

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance